Nattokinase (NSK-SD).

NSK-SD comes from the same natto fermentation that yields MK-7, and MK-7 is the cofactor for carboxylating the clotting factors, so it works against the fibrinolytic action. The standardised preparation is vitamin K2 reduced for that reason, and any added MK-7 should be declared on its own.

EPA displaces arachidonic acid at cyclooxygenase and lowers thromboxane A2, damping platelet aggregation while nattokinase acts on fibrin, so the two effects add across one sequence.

Ginkgolide B blocks platelet-activating factor signalling, so platelet aggregation is reduced at the same time fibrin breakdown is raised.

Garlic organosulfur compounds reduce platelet aggregation through thromboxane and calcium signalling, which adds to the separate fibrinolytic action.

Curcumin inhibits thromboxane synthesis and platelet activation, so pairing it with a standardised nattokinase compounds effects at two separate points.

Higher-intake alpha-tocopherol inhibits platelet protein kinase C and antagonises vitamin K-dependent carboxylation, both pushing in the same direction as nattokinase.

Salicin converts to salicylate, which inhibits platelet cyclooxygenase, so platelet function and fibrin breakdown move together.

Both are proteolytic enzymes that need enteric protection and an empty stomach to reach circulation rather than being spent on dietary protein, which is why they are formulated together.

Bromelain is the third standard member of systemic enzyme blends and carries its own action on fibrin and platelet aggregation, so the clotting effects add.

Lumbrokinase acts on the same fibrin substrate, so combining the two stacks one activity rather than adding a distinct mechanism.

Gingerols inhibit thromboxane synthase and platelet aggregation, adding to the separate fibrinolytic action.

Pine bark procyanidins lower platelet reactivity, so the pairing still stacks on normal clotting alongside the fibrinolytic action.

Quercetin inhibits platelet aggregation in laboratory preparations, an effect attributed to interference with collagen and thrombin signalling. Stacking it with a fibrinolytic enzyme puts two agents near the same physiology from different angles. Flag the overlap rather than presenting it as a benefit, and anyone on an antiplatelet or anticoagulant medicine should raise it with their prescriber.

Resveratrol reduces platelet aggregation in laboratory work, with cyclooxygenase inhibition among the proposed routes. Its very low oral bioavailability limits how much of that carries into a person. Combined with an enzyme acting on fibrin, the pairing is worth flagging for anyone already on a blood-thinning medicine.

Catechins have been reported to reduce platelet activation in laboratory systems. Green tea extract also carries vitamin K in leaf-derived preparations, which pushes in the opposite direction on clotting factor carboxylation. The net direction is not predictable, which is itself the reason to flag it.

Arginine is the substrate nitric oxide synthase uses to make nitric oxide, the endothelial signal that relaxes vascular smooth muscle. Nitric oxide also opposes platelet adhesion. Pairing it with a fibrinolytic enzyme means two agents acting on vascular tone and haemostasis at once, which matters for anyone already on a blood pressure medicine.

Dietary nitrate is reduced to nitrite by oral bacteria and then to nitric oxide in the tissues, a route independent of nitric oxide synthase. The result is vasodilation and a measurable fall in blood pressure readings. Combined with anything else affecting vascular tone the effects can add.

Magnesium antagonises calcium entry in vascular smooth muscle, which is the settled basis for its role in normal vascular tone. That is a separate mechanism from anything an enzyme does to fibrin. In a formula carrying both, the blood pressure side can add.

Potassium intake influences sodium handling at the kidney and vascular smooth muscle membrane potential, both established contributors to normal blood pressure regulation. It works on the electrolyte side while an enzyme works on fibrin. Anyone taking a potassium-sparing medicine should check the total potassium load with a prescriber.

Coenzyme Q10 shuttles electrons in the mitochondrial respiratory chain and acts as a lipid-phase antioxidant in its reduced ubiquinol form. Cardiac muscle has among the highest concentrations of it in the body. That is an energy and antioxidant role, entirely separate from fibrinolysis, which is why the two coexist without overlapping.

Taurine is present in cardiac and skeletal muscle at high concentration and participates in calcium handling and osmoregulation there. It is also a bile acid conjugation partner in the liver. Neither role touches fibrin, so the pairing is complementary rather than additive on the same axis.

Vitamin K is the cofactor for gamma-glutamyl carboxylase, the enzyme that carboxylates the glutamate residues in prothrombin and factors seven, nine and ten so they can bind calcium and function. A fibrinolytic enzyme acts on fibrin already formed, at the opposite end of the same cascade. The two therefore pull in opposing directions and anyone on a vitamin K antagonist medicine needs prescriber input before combining them.

Nattokinase is itself a protein, so it is a substrate for the gastric protease pepsin, which cleaves peptide bonds fastest at low pH. Taking supplemental pepsin alongside an oral protein enzyme works against that enzyme's survival to the intestine. This is the clearest anti-synergy in the set and it is straightforward chemistry.

Betaine hydrochloride is taken to lower gastric pH, which is exactly the condition that denatures a protein enzyme and activates pepsin against it. Co-dosing therefore reduces the amount of intact enzyme leaving the stomach. Separating the two in time is the practical response.

Bicarbonate neutralises gastric acid and raises luminal pH, which reduces both acid denaturation and pepsin activity against an ingested protein. That is the same logic behind formulating an acid-labile enzyme in a delayed-release capsule. It is a survival-of-the-enzyme consideration, not an effect on what the enzyme does.

Papain is a plant cysteine protease used in the same systemic enzyme blends as nattokinase, and both are proteolytic though they differ in catalytic mechanism and substrate preference. Blending proteases raises total proteolytic load rather than targeting fibrin more precisely. For anyone on a blood-thinning medicine the stacked load is the thing to disclose.

Boswellic acids act on 5-lipoxygenase and the leukotriene branch of eicosanoid signalling. That is a different arm of vascular and tissue signalling from fibrin turnover. The two appear together in enzyme and botanical blends as a formulation convention with no combination data behind it.